NEW YORK, Aug. 4, 2015 (GLOBE NEWSWIRE) -- Wedbush Securities, one of the nation's leading equity research firms and financial services providers, will host its annual Wedbush PacGrow Healthcare Management Access Conference on August 11 - 12, 2015. The conference, held in New York City, will bridge institutional investors with leading public and private companies. This will include management executives from firms specializing in biotechnology, medical devices, healthcare services, emerging pharmaceuticals, medical diagnostics, and life science tools.
Along with company presentations, the conference will also include panel discussions and roundtables led by Wedbush Equity Research analysts and various industry experts. The first panel discussion, "CEO Roundtable: Immuno-Oncology: Engineered T-Cells versus Engineered Antibodies," will include CEO speakers from the following companies: Bellicum Pharmaceuticals, MacroGenics, Inc., Xencor, and Unum Therapeutics. The second discussion, "Provider Payment Reforms: Dollar Redistribution, Winners and Losers," will be hosted by Wedbush Healthcare Research Analysts Tao Levy and Sarah James, and sponsored by Avalere Health, a leading health policy advisory firm.
"Wedbush PacGrow's annual healthcare conference continues three decades of tradition, bringing together the most innovative companies in the industry," states Scott T. Smith, Director of Healthcare Investment Banking. "We take exceptional pride in the fact that we have maintained our commitment to the space and our clients through both bull and bear markets, raising over $17 billion in capital for our clients across 240 transactions since 2005."
Companies scheduled to attend and present at the Wedbush PacGrow Healthcare Management Access Conference include: 3-V Biosciences, Achaogen, Adaptimmune Therapeutics, Anacor Pharmaceuticals, Applied Genetic Technologies, Arbutus Biopharma, Ardelyx, arGEN-X N.V., AxoGen, Bellicum Pharmaceuticals, Biodel, BioNano, Bluebird Bio, Blueprint Medicines, Carbylan Therapeutics, Cardica, Catabasis Pharmaceuticals, Cempra, Cepheid, CeQur, Cerulean Pharma, Cerus, Cidara Therapeutics, Dexcom, Dyax, Endocyte, Entellus Medical, Epirus Biopharmaceuticals, Epizyme, Exact Sciences Corp., Fate Therapeutics, Fibrocell Science, Flowonix Medical, Foundation Medicine, G1 Therapeutics, GenomeDx, Idera Pharmaceuticals, Infinity Pharmaceuticals, Intercept Pharmaceuticals, Intersect ENT, Intuitive Surgical, Karyopharm Therapeutics, Kura Oncology, Lazarus Effect, Lexicon Pharmaceuticals, Luminex, MacroGenics MEI Pharma, Mersana Therapeutics, miRagen Therapeutics, Mirati Therapeutics, Novavax, Omeros Corp, OvaScience, Pacira Pharmaceuticals, Prothena Corporation, PTC Therapeutics, Rapid Micro Biosystems, Regulus Therapeutics, Relypsa, ReVision Optics, Roka Bioscience, Sangamo BioSciences, Scholar Rock, Spectral Medical, Stemline Therapeutics, Sunesis Pharmaceuticals, Syros Pharmaceutical, Tandem Diabetes, Tenax Therapeutics, Tetraphase Pharmaceuticals, Theravance Biopharma, Trevena, Twist Bioscience, Ultragenyx Pharmaceuticals, United Therapeutics, Unum Therapeutics, Vascular Dynamics, VisionCare Ophthalmic Technologies, Vitae Pharmaceuticals, VolitionRx Ltd., Xencor, and Xoma.
Wedbush Equity Research offers in-depth and differentiated research coverage across the consumer, life sciences, technology, and industrial growth sectors. The team, comprised of 20 publishing analysts, generates timely, insightful analyses, along with the firm's award-winning "Wedbush Best Ideas List," an actively monitored compilation of stock ideas identifying outperformance trends over the forward six to twelve month period. Wedbush Equity Research consistently ranks among the industry's leading performance surveys, including Barron's and Zacks Investment Research's "Top Stock Picking Firm," Financial Times' "Top Analysts," Institutional Investor's "Rising Stars of Wall Street Research," Wall Street Journal's "Best of the Street," and StarMine's "Analyst Awards for Excellence."
The Wedbush PacGrow Healthcare Management Access Conference is by invitation only. Please contact the Wedbush Equity Research team at (213) 688-4529 for additional information.
About Wedbush Securities
Since our founding in 1955, Wedbush has been a leader in the financial industry providing our clients with a wide range of services; including retail and institutional sales, clearing services, equity research, corporate and municipal finance, equity market making, fixed income trading, and wealth management. Headquartered in Los Angeles, with over 100 registered offices, the firm focuses on relentless service, client financial safety, continuity, and advanced technology. Wedbush Securities is the largest subsidiary of holding company WEDBUSH, Inc., which also includes affiliated firms Wedbush Asset Management, Wedbush Capital Partners, Wedbush Opportunity Partners, and Lime Brokerage LLC.
Follow us on Twitter @Wedbush.